fbpx
Skip to content
Force Pharma Capital

Force Pharma Capital

Life Science Consulting, Business Development and Recruiting/Staffing
  • Home
  • About Us
  • Services
  • Pharmaceutical Blog
    • RLD
    • Excipients
    • Equipment
    • Health Technology
    • Regulatory Fees
  • Contact Us
  • FAQ
  • Portfolio

Pharmaceutical Information Blog

Channel in Nerve Cell May be Key in Unlocking Parkinson Disease Therapy

December 3, 2019 Blogger Leave a comment

Researchers have identified a channel in nerve cells that may serve as a new approach to targeting Parkinson disease. —…

Continue Reading →

Posted in: Health Technology Filed under: fixed dose combination, technology

Drug Trials Snapshots BRUKINSA | FDA

December 1, 2019 Blogger Leave a comment

Drug Trials Snapshots — Read on www.fda.gov/drugs/resources-information-approved-drugs/drug-trials-snapshots-brukinsa More inhibitors for oncology.

Continue Reading →

Posted in: Health Technology Filed under: approvals, FDA, pdufa

FDA Report: Changes in Marketplace Needed to Mitigate Drug Shortages

November 3, 2019 Blogger Leave a comment

The FDA Drug Shortages Task Force addressed the root causes of drug shortages and proposed potential solutions. — Read on…

Continue Reading →

Posted in: Health Technology Filed under: FDA

FDA Announces Availability of Draft Guidance – Type V DMFs for CDER-Led Combination Products Using Device Constituent Parts with Electronics or Software

October 28, 2019 Blogger Leave a comment

FDA Announces Availability of Draft Guidance – Type V DMFs for CDER-Led Combination Products Using Device Constituent Parts with Electronics…

Continue Reading →

Posted in: Health Technology Filed under: FDA, fixed dose combination

FDA approves new breakthrough therapy for cystic fibrosis | FDA

October 21, 2019 Blogger Leave a comment

FDA approves breakthrough therapy Trikafta for patients 12 and older with cystic fibrosis who have at least one F508del mutation…

Continue Reading →

Posted in: Health Technology Filed under: approvals, FDA, fixed dose combination, pdufa, technology

Blocking Inflammatory Pathway May Stop Brain Metastasis from Melanoma

October 20, 2019 Blogger Leave a comment

Melanoma brain metastasis occurs when tumor cells hijack an inflammatory pathway in the brain and blocking this pathway could prevent…

Continue Reading →

Posted in: Health Technology Filed under: FDA, technology

FDA Announces Availability of Draft Guidance – Drug Master Files

October 18, 2019 Blogger Leave a comment

FDA Announces Availability of Draft Guidance – Drug Master Files — Read on s2027422842.t.en25.com/e/es

Continue Reading →

Posted in: Uncategorized Filed under: FDA

Ceritinib Response Seen in Study of Brain Metastases in ALK-Positive NSCLC

October 12, 2019 Blogger Leave a comment

“The efficacy of ceritinib was evaluated in patients who have ALK-positive non-small cell lung cancer with active brain metastases.” —…

Continue Reading →

Posted in: Health Technology Filed under: FDA, pdufa

FDA approves new treatment for patients with migraine | FDA

October 11, 2019 Blogger Leave a comment

The U.S. Food and Drug Administration today approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine…

Continue Reading →

Posted in: Uncategorized Filed under: approvals, pdufa

Treating Pancreatic Cancer by Altering the Tumor Microbiome – National Cancer Institute

October 1, 2019 Blogger Leave a comment

In people with pancreatic cancer, the composition of their tumor microbiome might predict how long they live, according to a…

Continue Reading →

Posted in: Health Technology Filed under: fixed dose combination

Post navigation

Page 2 of 7
← Previous 1 2 3 … 7 Next →

Follow Us

Contact Us

  • Email
    forcepharma@icloud.com
  • Phone
    732-702-1824
  • Address
    265 Route 34 Lower Level, Colts Neck, New Jersey, 07722
Copyright © 2018 Force Pharma Capital